Evidence map›Paper›PMID 42419779›Full record

SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2026

COPD maintenance trials use heterogeneous outcomes and measurement instruments: a systematic literature review.

Vi Truong, Sulaiman Bin Safar, Sachin Ananth, Markus Fally, Augusta Beech, Sara Souto-Miranda, Nawar Diar Bakerly, Sarah L Gorst, Dave Singh, Jørgen Vestbo and 2 more

Abstract readSystematic Review
In one paragraph

Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vi TruongDivision of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Sulaiman Bin SafarDivision of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Sachin AnanthDepartment of Respiratory Medicine, Imperial College Healthcare NHS Trust, London, UK.ORCID https://orcid.org/0000-0002-6204-993X
Markus FallySection for Respiratory Medicine, Department of Internal Medicine, Zealand University Hospital - Roskilde, Roskilde, Denmark.ORCID https://orcid.org/0000-0002-1339-2918
Augusta BeechDivision of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0002-2690-5364
Sara Souto-MirandaDepartment of Physiotherapy, School of Health, Polytechnic University of Setúbal, Setúbal, Portugal.
Nawar Diar BakerlyDepartment of Respiratory Medicine, Salford Royal Hospital, Salford, UK.
Sarah L GorstDepartment of Health Data Science, University of Liverpool, Liverpool, UK.
Dave SinghDivision of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Jørgen VestboDivision of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0001-6355-6362
Lies LahousseDepartment of Bioanalysis, Ghent University, Ghent, Belgium.ORCID https://orcid.org/0000-0002-3494-4363
Alexander G MathioudakisDivision of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK Alexander.Mathioudakis@Manchester.ac.uk.ORCID https://orcid.org/0000-0002-4675-9616

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRandomised controlled trials (RCTs) of COPD management assess heterogeneous outcomes with diverse instruments and often omit those important to patients and healthcare professionals, limiting interpretability and comparability. This review aimed to identify the outcomes and instruments used in phase III/IV COPD maintenance management RCTs and assess their consistency.

methodsWe systematically reviewed all phase III/IV RCTs registered on ClinicalTrials.gov between 2010 and 2025 evaluating COPD maintenance management. Outcomes and measurement instruments were extracted from registry entries and categorised using the COMET (Core Outcome Measures in Effectiveness Trials) taxonomy. Registered outcomes from a random 10% sample were compared with the corresponding publications to assess concordance. Outcome frequencies were summarised across intervention types and sponsor categories.

results43 unique outcomes were identified across 240 eligible RCTs. Physiological (89.5%), clinical (85.0%) and life impact outcomes (63.8%) were most frequently assessed, whereas resource use (39.6%), safety (36.7%) and mortality (16.7%) outcomes were less commonly reported. Only lung function (76.3%) and health-related quality of life (57.5%) appeared in over half of the trials. Exacerbations were reported in 40.4% of studies, while several patient-prioritised outcomes, particularly activities of daily living (5.4%) and exercise tolerance (18.3%), were infrequently assessed. Industry-sponsored RCTs more often reported lung function, resource use and adverse events; non-industry trials more frequently included biomarkers. Concordance between registered and published outcomes was acceptable (79.7%), although safety outcomes and instruments were sometimes under-reported.

conclusionCOPD maintenance management RCTs show substantial heterogeneity and incomplete assessment of patient-prioritised outcomes. An internationally representative, multi-stakeholder core outcome set is urgently needed to improve consistency and patient-centred evaluation in future trials.

Indexed as

Endpoint DeterminationLungPulmonary Disease, Chronic ObstructiveRandomized Controlled Trials as TopicResearch DesignClinical Trials, Phase III as TopicHumansPredictive Value of TestsQuality of LifeTreatment Effect HeterogeneityTreatment Outcome

Identifiers

PMID42419779
PMCPMC13343203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.